A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

European Journal of Cancer

Volumn 49, Issue 14, 2013, Pages 2972-2978

  Liu, Joyce F ^a   Tolaney, Sara M ^a   Birrer, Michael ^b   Fleming, Gini F ^c   Buss, Mary K ^d   Dahlberg, Suzanne E ^a   Lee, Hang ^b   Whalen, Christin ^a   Tyburski, Karin ^a   Winer, Eric ^a   Ivy, Percy ^e   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anti angiogenic; Breast; Cediranib; Olaparib; Ovarian; PARP inhibitor; Phase 1

Indexed keywords

CEDIRANIB; OLAPARIB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG DOSE ESCALATION; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INTESTINE OBSTRUCTION; NEUTROPENIA; OPEN STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TABLET; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; UTERINE TUBE; UTERUS CANCER;

ANTI-ANGIOGENIC; BREAST; CEDIRANIB; OLAPARIB; OVARIAN; PARP-INHIBITOR; PHASE 1;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CAPSULES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TABLETS; TREATMENT OUTCOME;

EID: 84883054717     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.020     Document Type: Article

References (23)

1. J.C. Ame, C. Spenlehauer, and G. de Murcia The PARP superfamily Bioessays 26 8 2004 882 893
2. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 22 2008 3785 3790
3. N. McCabe, N.C. Turner, and C.J. Lord Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 16 2006 8109 8115
4. H.E. Bryant, N. Schultz, and H.D. Thomas Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 7035 2005 913 917
5. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 7035 2005 917 921
6. M.W. Audeh, J. Carmichael, and R.T. Penson Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 9737 2010 245 251
7. A. Tutt, M. Robson, and J.E. Garber Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 9737 2010 235 244
8. K.A. Gelmon, M. Tischkowitz, and H. Mackay Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol 12 9 2011 852 861
9. J. Balmana, N.M. Tung, and S.J. Isakoff Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors J Clin Oncol 2012 [abstr. 1009]
10. A. Rajan, C.A. Carter, and R.J. Kelly A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors Clin Cancer Res 18 8 2012 2344 2351
11. E. Dean, M.R. Middleton, and T. Pwint Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours Br J Cancer 106 3 2012 468 474
12. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 2007 5165 5171
13. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186
14. U.A. Matulonis, S. Berlin, and P. Ivy Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 33 2009 5601 5606
15. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New Engl J Med 357 26 2007 2666 2676
16. E.L. Mayer, S. Hamell, and J. Savoie AZD2171 for refractory breast cancer: a phase 2 trial Breast Cancer Res Treat 106 Suppl. 1 2007 S274 [abstr. 6080]
17. L. Tentori, P.M. Lacal, and A. Muzi Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis Eur J Cancer 43 14 2007 2124 2133
18. R.S. Bindra, S.L. Gibson, and A. Meng Hypoxia-induced down-regulation of BRCA1 expression by E2Fs Cancer Res 65 24 2005 11597 11604
19. R.S. Bindra, P.J. Schaffer, and A. Meng Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells Mol Cell Biol 24 19 2004 8504 8518
20. N. Chan, and R.G. Bristow "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair Clin Cancer Res 16 18 2010 4553 4560
21. D.C. Hegan, Y. Lu, and G.C. Stachelek Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 Proc Natl Acad Sci U S A 107 5 2010 2201 2206
22. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 10 Suppl. 2003 187s 193s
23. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 2009 123 134